Cervical Human Papillomavirus (HPV) INFECTION. High risk human papillomavirus (HPV)
Conditions
Interventions
Intervention 1: Intervention group: Participants in the intervention group will receive a vaginal Lactovage suppository (single dose of 500 mg, Zist Takhmir Company) once daily for 6 month. Interventi
Sponsors
Karaj University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
25 Years to No maximum
Inclusion criteria
Inclusion criteria: Women infected with High-risk HPV No use of immunosuppressive drugs or chemotherapy Age over 25 years No probiotic use during the past 6 weeks No immune system deficiency or AIDS No cervical intraepithelial neoplasia requiring conization No cervical cancer Not pregnant Abnormal cervical Pap smear results
Exclusion criteria
Exclusion criteria: Cervical cancer Pregnancy during the study Use of immunosuppressive drugs or chemotherapy Immunodeficiency or AIDS Cervical intraepithelial neoplasia requiring conization
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of negative HPV test result 6 months after the start of the intervention. Timepoint: 6 months from the start of receiving the medication. Method of measurement: Cervical HPV test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in Pap smear cytology. Timepoint: 6 months from the start of receiving the medication. Method of measurement: Pap smear test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShima Mohamadian
Karaj University of Medical Sciences
Outcome results
None listed